H.L.  Li

Dr. H.L. Li


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2019 in RSC Advances
Verified
Journal Article
Open access
YBYao Bai
Yao Bai
LCLingling Chen
Lingling Chen
YCYao Chen
Yao Chen
XCXinmeng Chen
Xinmeng Chen
YDYilong Dong
Yilong Dong
HLH.L. Li
H.L. Li
PGM ameliorates AD-like pathology and cognitive impairments by enhancing microglial amyloid-β clearance.

24 August 2023 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
XZXue-Mei Zheng
Xue-Mei Zheng
YCYuan-Si Chen
Yuan-Si Chen
YBYu-Juan Ban
Yu-Juan Ban
YWYu-Jie Wang
Yu-Jie Wang
YDYong-Xi Dong
Yong-Xi Dong
JZJiquan Zhang
Jiquan Zhang

27 September 2022 in Organic Chemistry Frontiers
Verified
Journal Article
Closed access
PDF file
XCXiaojia Cai
Xiaojia Cai
JXJinyuan Xu
Jinyuan Xu
XCXueli Cui
Xueli Cui
JQJing Qu
Jing Qu
WSWeiqiang Sun
Weiqiang Sun
JWJia-Qiang Wu
Jia-Qiang Wu
An efficient, sustainable and straightforward method is reported for the synthesis of a series of α,α-difluoromethyl carbinols via K2CO3-triggered Friedel–Crafts reaction of electron-rich arenes using the stable and easily affordable 2,2-difluorovinyl arylsulfonate.

14 May 2025 in Phytomedicine
Verified
Journal Article
Closed access
YZYunjie Zhao
Yunjie Zhao
XSXingzong Sun
Xingzong Sun
FSFaling Shao
Faling Shao
LLLin Li
Lin Li
WXWeilie Xiao
Weilie Xiao
HBHongkun Bao
Hongkun Bao

15 September 2022 in Fitoterapia
Verified
Journal Article
Closed access
JHJia-Bi Huang
Jia-Bi Huang
YCYuan-Si Chen
Yuan-Si Chen
MWMeng-Ru Wang
Meng-Ru Wang
RLRong-Shuai Li
Rong-Shuai Li
XZXue-Rong Zhao
Xue-Rong Zhao
WXWeilie Xiao
Weilie Xiao

19 November 2020 in PeerJ
Verified
Journal Article
Open access
PDF file
TDTianqi Dong
Tianqi Dong
YYYuncang Yuan
Yuncang Yuan
XXXudong Xiang
Xudong Xiang
SSShuping Sang
Shuping Sang
HSHao Shen
Hao Shen
SZShangyong Zheng
Shangyong Zheng
Purpose: Yes associated protein 1 (YAP1), which is a standout amongst the most essential effectors of the Hippo pathway, assumes a vital part in a few kinds of cancer. However, whether YAP1 is an oncogene in CRC (colorectal cancer) remains controversial, and the association between the subcellular localization of YAP1 and clinical implications in CRC remains unknown. Patients and methods: In this study, we investigated the subcellular localization of YAP1 in CRC cells by immunohistochemistry and then associate these findings with clinical information in a large CRC cohort with 919 CRC patients. Results: The results show that CRC tissues has a significant higher expression of cytoplasmic YAP1 compared to adjacent normal tissues (all P < 0.001). Cytoplasmic YAP1 expression was significantly associated with the number of lymph nodes removed and differentiation grade (all P < 0.001). Furthermore, after correcting confounding variables, for example, TNM stage and differentiation grade, the multivariate Cox analysis confirmed cytoplasmic YAP1-high subgroup had a significant shorter DFS (HR = 3.255; 95% CI [2.290–4.627]; P < 0.001) and DSS (HR = 4.049; 95% CI [2.400–6.830]; P < 0.001) than cytoplasmic YAP1-low subgroup. High cytoplasmic YAP1 expression is associated with a worse survival in stage III CRC patients who received chemotherapy. Conclusion: Cytoplasmic YAP1 could be could be utilized as a prognosis factor in CRC patients, and may be an indicator of whether certain patients population could benefit from postoperative chemotherapy.